A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas
about
Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approachG protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenuesTreatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumors.The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.Neurokinin-1 receptor directly mediates glioma cell migration by up-regulation of matrix metalloproteinase-2 (MMP-2) and membrane type 1-matrix metalloproteinase (MT1-MMP).Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells.High expression of substance P and its receptor neurokinin-1 receptor in colorectal cancer is associated with tumor progression and prognosis.Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease.Involvement of substance P and the NK-1 receptor in pancreatic cancer.NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011.β-Arrestin 1 has an essential role in neurokinin-1 receptor-mediated glioblastoma cell proliferation and G2/M phase transition.Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.Association of genetic variants in tachykinins pathway genes with colorectal cancer risk.The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.Substance P immunoreactive nerve fibres are related to gastric cancer differentiation status and could promote proliferation and migration of gastric cancer cells.Truncation of neurokinin-1 receptor-Negative regulation of substance P signaling.The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer
P2860
Q26739681-F8E64091-0FA0-4671-8DB6-8ABB546118D8Q26825769-04D98A54-EDB1-458A-AB77-74EC78139E8FQ33599638-0BFF1565-FE8B-4ADB-B9C5-BEDB60AB8743Q34475975-3774D767-A2EA-4F5F-B006-8CB23280A8AFQ36508615-C9F93064-DB7B-4E24-A366-6B43EE8B8931Q37004651-7CDEDE05-863D-4073-BB48-23B7AEC505DAQ37021243-3085C7C6-EB1E-4D04-9CDA-13B502B76D54Q37593097-F99AAE6E-4975-4089-ACA0-82E276157053Q37617971-C80C9716-2C64-4E2E-963D-8B2D88E13B45Q38018635-656EE91E-9451-4505-911B-0308D5CA8732Q38710607-49481837-13FB-408F-886D-1CC897E8DDE2Q38816965-870B44C6-6DA9-4AF4-84A9-89DCFD18195EQ39596926-DF361C57-E6FA-442A-A23B-D2CE70BF202DQ39625473-0AB6038C-1377-46E4-AF6C-4EF0D31FB76AQ39629842-8F99CB20-63F7-4B6D-94A8-470266300D20Q49972918-080D7F7B-8209-44C4-B52F-73492DB26F55Q58914868-5437717C-0670-4D51-91FD-9353E8F96657
P2860
A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A constitutively active form o ...... ted apoptosis in glioblastomas
@en
A constitutively active form o ...... ed apoptosis in glioblastomas.
@nl
type
label
A constitutively active form o ...... ted apoptosis in glioblastomas
@en
A constitutively active form o ...... ed apoptosis in glioblastomas.
@nl
prefLabel
A constitutively active form o ...... ted apoptosis in glioblastomas
@en
A constitutively active form o ...... ed apoptosis in glioblastomas.
@nl
P2093
P2860
P1476
A constitutively active form o ...... ted apoptosis in glioblastomas
@en
P2093
Elizabeth A Cox
Laura E Goldsmith
Madan M Kwatra
Mark D Richardson
Shawn G Kwatra
Toshimasa Akazawa
P2860
P304
P356
10.1111/J.1471-4159.2009.06032.X
P407
P50
P577
2009-03-11T00:00:00Z